BIOMAT Database Logo BIOMAT Database Logo

Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance. 2011

Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
St John's National Academy of Health Sciences, Bangalore, India.

Prevalence of etravirine genotypic resistance was assessed among 92 HIV-1C-infected patients failing nevirapine and efavirenz-based regimens from a cohort of 552 Indian patients. Overall, prevalence of etravirine cross-resistance identified using the Tibotec Weighted Score was 41% (31.5% intermediately-resistant and 9.8% fully-resistant). The most frequently described nonnucleoside reverse transcriptase inhibitor-associated mutations included Y181 (35.9%), K101 (20.7%), G190 (17.4%), and V108 (15.2%). The resistant group demonstrated higher viral load (P = 0.01) and longer duration of antiretroviral treatment (P = 0.03) compared with the susceptible group.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.
May 2011, Antimicrobial agents and chemotherapy,
Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
April 2011, Antimicrobial agents and chemotherapy,
Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.
March 2006, AIDS research and human retroviruses,
Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
April 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
January 2010, Antimicrobial agents and chemotherapy,
Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.
November 2014, AIDS (London, England),
Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.
March 2013, AIDS (London, England),
Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
January 1996, Biochemistry,
Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
August 2019, Antimicrobial agents and chemotherapy,
Ujjwal Neogi, and Anita Shet, and Ranjani Shamsundar, and Maria L Ekstrand
Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
May 2008, AIDS (London, England),
Copied contents to your clipboard!